Download available for users with full-size access enabled
Eloxatin
A new hope in the adjuvant treatment of colon cancer
New indication
Eloxatin
Now indicated in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) as adjuvant treatment of patients with stage III (Dukes’ C) colon cancer after complete resection of primary tumor
ELOXATIN in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) is indicated as adjuvant treatment of patients with stage III (Dukes' C) colon cancer after complete resection of primary tumor. The indication is based on a demonstrated improvement in disease-free survival. Survival data at 6 years show a numerical improvement in overall survival. The efficacy of ELOXATIN on disease-free survival benefit in patients 265 years of age was not conclusive in the adjuvant trial.
ELOXATIN in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) is also indicated for the treatment of metastatic colorectal cancer.
Eloxatin
OXALIPLATIN for injection
A proven choice
sanofi aventis
Brand: Eloxatin Country/Market: Canada, North America Target: Healthcare Professional (HCP) Tagline: A proven choice Size/duration: Single-page Publication/Aired:
Oncology Exchange - May 2008
See more Eloxatin ads here
Eloxatin